Tropicamide/phenylephrine

Tropicamide/phenylephrine, sold under the brand name Mydcombi is a fixed dose combination of tropicamide and phenylephrine used to dilate the eyes (mydriasis). It contains, tropicamide, an anticholinergic, and phenylephrine, as the hydrochloride, an alpha-1 adrenergic receptor agonist. It is sprayed into the eyes.It was approved for medical use in the United States in May 2023.

Medical uses
Tropicamide/phenylephrine is used for the short-term dilation of the pupils.

References
External links
Clinical trial number NCT03751631 for "Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation (MIST-1)" at ClinicalTrials.gov
Clinical trial number NCT03751098 for "Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation (MIST-2)" at ClinicalTrials.gov